;PMID: 12485954
;source_file_971.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..255] = [t:45..255]
;2)section:[e:259..322] = [t:259..322]
;3)section:[e:326..441] = [t:326..441]
;4)sentence:[e:445..591] = [t:445..591]
;5)sentence:[e:592..815] = [t:592..815]
;6)sentence:[e:816..944] = [t:816..944]
;7)sentence:[e:945..1053] = [t:945..1053]
;8)sentence:[e:1054..1282] = [t:1054..1282]
;9)sentence:[e:1283..1486] = [t:1283..1486]
;10)sentence:[e:1487..1625] = [t:1487..1625]
;11)sentence:[e:1626..1843] = [t:1626..1843]
;12)sentence:[e:1844..1961] = [t:1844..1961]
;13)sentence:[e:1962..2114] = [t:1962..2114]
;14)section:[e:2118..2163] = [t:2118..2163]

;section 0 Span:0..39
;Drug Metab Dispos. 2003 Jan;31(1):60-6.
(SEC
  (FRAG (NNP:[0..4] Drug) (NNP:[5..10] Metab) (NNP:[11..17] Dispos)
        (.:[17..18] .) (CD:[19..23] 2003) (CC:[24..31] Jan;31-LRB-)
        (CD:[31..32] 1) (-RRB-:[32..33] -RRB-) (CD:[33..36] :60)
        (HYPH:[36..37] -) (CD:[37..39] 6.)))

;sentence 1 Span:45..255
;Differences in cytochrome P450 forms involved in the metabolism of 
;N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine
;monohydrochloride  (NE-100), a novel sigma ligand, in human liver and
;intestine.
;[60..81]:cyp450:"cytochrome P450 forms"
;[113..192]:substance:"N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethy
;lamine monohydrochloride"
;[195..201]:substance:"NE-100"
;[212..224]:substance:"sigma ligand"
(SENT
  (NP-HLN
    (NP (NNS:[45..56] Differences))
    (PP (IN:[57..59] in)
      (NP
        (NP
          (NML (NN:[60..70] cytochrome) (NN:[71..75] P450))
          (NNS:[76..81] forms))
        (VP (VBN:[82..90] involved)
          (NP (-NONE-:[90..90] *))
          (PP-CLR (IN:[91..93] in)
            (NP
              (NP (DT:[94..97] the) (NN:[98..108] metabolism))
              (PP (IN:[109..111] of)
                (NP
                  (NP
                    (NP
                        (NN:[113..174] N,N-dipropyl-2--LSB-4-methoxy-3--LRB-2-phenylethoxy-RRB-phenyl-RSB-ethylamine)
                        (NN:[175..192] monohydrochloride))
                    (NP (-LRB-:[194..195] -LRB-) (NN:[195..201] NE-100)
                        (-RRB-:[201..202] -RRB-)))
                  (,:[202..203] ,)
                  (NP (DT:[204..205] a) (JJ:[206..211] novel)
                     (SYM:[212..217] sigma) (NN:[218..224] ligand))))))
          (,:[224..225] ,)
          (PP (IN:[226..228] in)
            (NP
              (NP
                (ADJP-1 (JJ:[229..234] human))
                (NN:[235..240] liver))
              (CC:[241..244] and)
              (NP
                (ADJP-1 (-NONE-:[244..244] *P*))
                (NN:[245..254] intestine)))))))
    (.:[254..255] .)))

;section 2 Span:259..322
;Yamamoto T, Hagima N, Nakamura M, Kohno Y, Nagata K, Yamazoe Y.
(SEC
  (FRAG (NNP:[259..267] Yamamoto) (NNP:[268..269] T) (,:[269..270] ,)
        (NNP:[271..277] Hagima) (NNP:[278..279] N) (,:[279..280] ,)
        (NNP:[281..289] Nakamura) (NNP:[290..292] M,) (NNP:[293..298] Kohno)
        (NNP:[299..300] Y) (,:[300..301] ,) (NNP:[302..308] Nagata)
        (NNP:[309..310] K) (,:[310..311] ,) (NNP:[312..319] Yamazoe)
        (NNP:[320..322] Y.)))

;section 3 Span:326..441
;Department of Drug Metabolism, Taisho Pharmaceutical Co, Ltd, Saitama, Japan.
; takahito.yamamoto@po.rd.taisho.co.jp
(SEC
  (FRAG (NNP:[326..336] Department) (IN:[337..339] of) (NNP:[340..344] Drug)
        (NNP:[345..355] Metabolism) (,:[355..356] ,) (NNP:[357..363] Taisho)
        (NNP:[364..378] Pharmaceutical) (NNP:[379..381] Co) (NNP:[381..382] ,)
        (NNP:[383..386] Ltd) (,:[386..387] ,) (NNP:[388..395] Saitama)
        (,:[395..396] ,) (NNP:[397..402] Japan) (.:[402..403] .)
        (``:[405..428] takahito.yamamoto@po.rd) (NN:[428..441] .taisho.co.jp)))

;sentence 4 Span:445..591
;N,N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine
;monohydrochloride  (NE-100) has been developed to treat subjects with
;schizophrenia.
;[445..524]:substance:"N,N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethy
;lamine monohydrochloride"
;[527..533]:substance:"NE-100"
(SENT
  (S
    (NP-SBJ-1
      (NP
          (NN:[445..506] N,N-Dipropyl-2--LSB-4-methoxy-3--LRB-2-phenylethoxy-RRB-phenyl-RSB-ethylamine)
          (NN:[507..524] monohydrochloride))
      (NP (-LRB-:[526..527] -LRB-) (NN:[527..533] NE-100)
          (-RRB-:[533..534] -RRB-)))
    (VP (VBZ:[535..538] has)
      (VP (VBN:[539..543] been)
        (VP (VBN:[544..553] developed)
          (NP-1 (-NONE-:[553..553] *))
          (S-PRP
            (NP-SBJ (-NONE-:[553..553] *))
            (VP (TO:[554..556] to)
              (VP (VB:[557..562] treat)
                (NP
                  (NP (NNS:[563..571] subjects))
                  (PP (IN:[572..576] with)
                    (NP (NN:[577..590] schizophrenia))))))))))
    (.:[590..591] .)))

;sentence 5 Span:592..815
;This drug is  mainly excreted in the form of oxidative metabolites. In the
;present study,  identification of p450 forms involved in the metabolism was
;carried out using  human livers and intestinal microsomes (HLM and HIM).
;[597..601]:substance:"drug"
;[637..658]:substance:"oxidative metabolites"
;[701..711]:cyp450:"p450 forms"
(SENT
  (S
    (NP-SBJ-1 (DT:[592..596] This) (NN:[597..601] drug))
    (VP (VBZ:[602..604] is)
      (ADVP (RB:[606..612] mainly))
      (VP (VBN:[613..621] excreted)
        (NP-1 (-NONE-:[621..621] *))
        (PP (IN:[622..624] in)
          (NP
            (NP (DT:[625..628] the) (NN:[629..633] form))
            (PP (IN:[634..636] of)
              (NP (JJ:[637..646] oxidative) (NNS:[647..658] metabolites)))))))
    (.:[658..659] .))
  (S
    (PP (IN:[660..662] In)
      (NP (DT:[663..666] the) (JJ:[667..674] present) (NN:[675..680] study)))
    (,:[680..681] ,)
    (NP-SBJ-2
      (NP (NN:[683..697] identification))
      (PP (IN:[698..700] of)
        (NP
          (NP (NN:[701..705] p450) (NNS:[706..711] forms))
          (VP (VBN:[712..720] involved)
            (NP (-NONE-:[720..720] *))
            (PP-CLR (IN:[721..723] in)
              (NP (DT:[724..727] the) (NN:[728..738] metabolism)))))))
    (VP (VBD:[739..742] was)
      (VP (VBN:[743..750] carried)
        (NP-2 (-NONE-:[750..750] *))
        (PRT (RP:[751..754] out))
        (S-MNR
          (NP-SBJ (-NONE-:[754..754] *))
          (VP (VBG:[755..760] using)
            (NP
              (NP
                (NP
                  (ADJP-4 (JJ:[762..767] human))
                  (NNS:[768..774] livers)
                  (NML-3 (-NONE-:[774..774] *P*)))
                (CC:[775..778] and)
                (NP
                  (ADJP-4 (-NONE-:[778..778] *P*))
                  (JJ:[779..789] intestinal)
                  (NML-3 (NNS:[790..800] microsomes))))
              (NP (-LRB-:[801..802] -LRB-) (NN:[802..805] HLM)
                  (CC:[806..809] and) (NN:[810..813] HIM)
                  (-RRB-:[813..814] -RRB-)))))))
    (.:[814..815] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[592..815]::S:S:

;sentence 6 Span:816..944
;Eadie-Hofstee plots for  NE-100 disappearance in HLM were biphasic, thus
;indicating the involvement of at  least two p450 forms.
;[841..847]:substance:"NE-100"
;[933..943]:cyp450:"p450 forms"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (NNP:[816..821] Eadie) (HYPH:[821..822] -) (NNP:[822..829] Hofstee))
        (NNS:[830..835] plots))
      (PP (IN:[836..839] for)
        (NP
          (NP (NN:[841..847] NE-100) (NN:[848..861] disappearance))
          (PP-LOC
            (NP (IN:[862..864] in))
            (NN:[865..868] HLM)))))
    (VP (VBD:[869..873] were)
      (ADJP-PRD (JJ:[874..882] biphasic))
      (,:[882..883] ,)
      (SBAR-ADV (RB:[884..888] thus)
        (S
          (NP-SBJ (-NONE-:[888..888] *))
          (VP (VBG:[889..899] indicating)
            (NP
              (NP (DT:[900..903] the) (NN:[904..915] involvement))
              (PP (IN:[916..918] of)
                (NP
                  (QP (IN:[919..921] at) (JJS:[923..928] least)
                      (CD:[929..932] two))
                   (NN:[933..937] p450) (NNS:[938..943] forms))))))))
    (.:[943..944] .)))

;sentence 7 Span:945..1053
;The metabolism of NE-100 was mediated with recombinant  CYP1A1, CYP1A2,
;CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
;[963..969]:substance:"NE-100"
;[1001..1007]:cyp450:"CYP1A1"
;[1009..1015]:cyp450:"CYP1A2"
;[1017..1023]:cyp450:"CYP2C9"
;[1025..1032]:cyp450:"CYP2C19"
;[1034..1040]:cyp450:"CYP2D6"
;[1046..1052]:cyp450:"CYP3A4"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[945..948] The) (NN:[949..959] metabolism))
      (PP (IN:[960..962] of)
        (NP (NN:[963..969] NE-100))))
    (VP (VBD:[970..973] was)
      (VP (VBN:[974..982] mediated)
        (NP-2 (-NONE-:[982..982] *))
        (PP-MNR (IN:[983..987] with)
          (NP
            (NP
              (ADJP-1 (JJ:[988..999] recombinant))
              (NN:[1001..1007] CYP1A1))
            (,:[1007..1008] ,)
            (NP
              (ADJP-1 (-NONE-:[1008..1008] *P*))
              (NN:[1009..1015] CYP1A2))
            (,:[1015..1016] ,)
            (NP
              (ADJP-1 (-NONE-:[1016..1016] *P*))
              (NN:[1017..1023] CYP2C9))
            (,:[1023..1024] ,)
            (NP
              (ADJP-1 (-NONE-:[1024..1024] *P*))
              (NN:[1025..1032] CYP2C19))
            (,:[1032..1033] ,)
            (NP
              (ADJP-1 (-NONE-:[1033..1033] *P*))
              (NN:[1034..1040] CYP2D6))
            (,:[1040..1041] ,) (CC:[1042..1045] and)
            (NP
              (ADJP-1 (-NONE-:[1045..1045] *P*))
              (NN:[1046..1052] CYP3A4))))))
    (.:[1052..1053] .)))

;sentence 8 Span:1054..1282
;A significant correlation  was observed between activities of NE-100
;metabolism and dextromethorphan  O-demethylation (a specific activity for
;CYP2D6) or testosterone  6beta-hydroxylation (a specific activity for CYP3A4)
;in HLM.
;[1116..1122]:substance:"NE-100"
;[1138..1154]:substance:"dextromethorphan"
;[1197..1203]:cyp450:"CYP2D6"
;[1208..1220]:substance:"testosterone"
;[1267..1273]:cyp450:"CYP3A4"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1054..1055] A) (JJ:[1056..1067] significant)
          (NN:[1068..1079] correlation))
      (PP-1 (-NONE-:[1079..1079] *ICH*)))
    (VP (VBD:[1081..1084] was)
      (VP (VBN:[1085..1093] observed)
        (NP-2 (-NONE-:[1093..1093] *))
        (PP-1 (IN:[1094..1101] between)
          (NP
            (NP (NNS:[1102..1112] activities))
            (PP (IN:[1113..1115] of)
              (NP
                (NP (NN:[1116..1122] NE-100) (NN:[1123..1133] metabolism))
                (CC:[1134..1137] and)
                (NP
                  (NP (NN:[1138..1154] dextromethorphan)
                      (NN:[1156..1171] O-demethylation)
                    (PRN (-LRB-:[1172..1173] -LRB-)
                      (NP
                        (NP (DT:[1173..1174] a) (JJ:[1175..1183] specific)
                            (NN:[1184..1192] activity))
                        (PP (IN:[1193..1196] for)
                          (NP (NN:[1197..1203] CYP2D6))))
                      (-RRB-:[1203..1204] -RRB-)))
                  (CC:[1205..1207] or)
                  (NP (NN:[1208..1220] testosterone)
                      (NN:[1222..1241] 6beta-hydroxylation)
                    (PRN (-LRB-:[1242..1243] -LRB-)
                      (NP
                        (NP (DT:[1243..1244] a) (JJ:[1245..1253] specific)
                            (NN:[1254..1262] activity))
                        (PP (IN:[1263..1266] for)
                          (NP (NN:[1267..1273] CYP3A4))))
                      (-RRB-:[1273..1274] -RRB-))))))))
        (PP-LOC (IN:[1275..1277] in)
          (NP (NN:[1278..1281] HLM)))))
    (.:[1281..1282] .)))

;sentence 9 Span:1283..1486
;The activity of  NE-100 metabolism was inhibited by approximately 80% by an
;anti-CYP2D6 antibody  and only by quinidine among the p450-selective
;inhibitors at a low substrate  concentration (0.1 microM).
;[1300..1306]:substance:"NE-100"
;[1335..1352]:quantitative-value:"approximately 80%"
;[1359..1379]:substance:"anti-CYP2D6 antibody"
;[1393..1402]:substance:"quinidine"
;[1413..1417]:cyp450:"p450"
;[1428..1438]:substance:"inhibitors"
;[1448..1457]:substance:"substrate"
;[1474..1477]:quantitative-value:"0.1"
;[1478..1484]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1283..1286] The) (NN:[1287..1295] activity))
      (PP (IN:[1296..1298] of)
        (NP (NN:[1300..1306] NE-100) (NN:[1307..1317] metabolism))))
    (VP (VBD:[1318..1321] was)
      (VP (VBN:[1322..1331] inhibited)
        (NP-1 (-NONE-:[1331..1331] *))
        (PP-EXT (IN:[1332..1334] by)
          (NP
            (QP (RB:[1335..1348] approximately) (CD:[1349..1351] 80))
            (NN:[1351..1352] %)))
        (PP
          (PP (IN:[1353..1355] by)
            (NP-LGS (DT:[1356..1358] an)
              
              (NML (AFX:[1359..1363] anti) (HYPH:[1363..1364] -)
                   (NN:[1364..1370] CYP2D6))
              (NN:[1371..1379] antibody)))
          (CC:[1381..1384] and)
          (PP
            (ADVP (RB:[1385..1389] only))
            (IN:[1390..1392] by)
            (NP-LGS
              (NP (NN:[1393..1402] quinidine))
              (PP (IN:[1403..1408] among)
                (NP (DT:[1409..1412] the)
                  (NML (NN:[1413..1417] p450) (HYPH:[1417..1418] -)
                       (JJ:[1418..1427] selective))
                  (NNS:[1428..1438] inhibitors))))))
        (PP (IN:[1439..1441] at)
          (NP (DT:[1442..1443] a) (JJ:[1444..1447] low)
              (NN:[1448..1457] substrate) (NN:[1459..1472] concentration)
            (PRN (-LRB-:[1473..1474] -LRB-)
              (NP (CD:[1474..1477] 0.1) (NN:[1478..1484] microM))
              (-RRB-:[1484..1485] -RRB-))))))
    (.:[1485..1486] .)))

;sentence 10 Span:1487..1625
;In contrast, with a high substrate concentration (10  microM), the activity
;was inhibited by an anti-CYP3A4 antibody and by  ketoconazole.
;[1512..1521]:substance:"substrate"
;[1537..1539]:quantitative-value:"10"
;[1541..1547]:quantitative-units:"microM"
;[1583..1603]:substance:"anti-CYP3A4 antibody"
;[1612..1624]:substance:"ketoconazole"
(SENT
  (S
    (PP (IN:[1487..1489] In)
      (NP (NN:[1490..1498] contrast)))
    (,:[1498..1499] ,)
    (PP (IN:[1500..1504] with)
      (NP (DT:[1505..1506] a) (JJ:[1507..1511] high) (NN:[1512..1521] substrate)
          (NN:[1522..1535] concentration)
        (PRN (-LRB-:[1536..1537] -LRB-)
          (NP (CD:[1537..1539] 10) (NN:[1541..1547] microM))
          (-RRB-:[1547..1548] -RRB-))))
    (,:[1548..1549] ,)
    (NP-SBJ-1 (DT:[1550..1553] the) (NN:[1554..1562] activity))
    (VP (VBD:[1563..1566] was)
      (VP (VBN:[1567..1576] inhibited)
        (NP-1 (-NONE-:[1576..1576] *))
        (PP
          (PP (IN:[1577..1579] by)
            (NP-LGS (DT:[1580..1582] an)
              
              (NML (AFX:[1583..1587] anti) (HYPH:[1587..1588] -)
                   (NN:[1588..1594] CYP3A4))
              (NN:[1595..1603] antibody)))
          (CC:[1604..1607] and)
          (PP (IN:[1608..1610] by)
            (NP-LGS (NN:[1612..1624] ketoconazole))))))
    (.:[1624..1625] .)))

;sentence 11 Span:1626..1843
;On the other hand, in HIM, the Eadie-Hofstee plots for NE-100  disappearance
;were monophasic, and the metabolism was strongly inhibited by an  anti-CYP3A4
;antibody and by ketoconazole but not by other inhibitors used.
;[1681..1687]:substance:"NE-100"
;[1769..1789]:substance:"anti-CYP3A4 antibody"
;[1797..1809]:substance:"ketoconazole"
;[1827..1837]:substance:"inhibitors"
(SENT
  (S
    (S
      (PP (IN:[1626..1628] On)
        (NP (DT:[1629..1632] the) (JJ:[1633..1638] other) (NN:[1639..1643] hand)))
      (,:[1643..1644] ,)
      (PP-LOC (IN:[1645..1647] in)
        (NP (NN:[1648..1651] HIM)))
      (,:[1651..1652] ,)
      (NP-SBJ
        (NP (DT:[1653..1656] the)
          (NML (NNP:[1657..1662] Eadie) (HYPH:[1662..1663] -)
               (NNP:[1663..1670] Hofstee))
          (NNS:[1671..1676] plots))
        (PP (IN:[1677..1680] for)
          (NP (NN:[1681..1687] NE-100) (NN:[1689..1702] disappearance))))
      (VP (VBD:[1703..1707] were)
        (ADJP-PRD (JJ:[1708..1718] monophasic))))
    (,:[1718..1719] ,) (CC:[1720..1723] and)
    (S
      (NP-SBJ-1 (DT:[1724..1727] the) (NN:[1728..1738] metabolism))
      (VBD:[1739..1742] was)
      (VP
        (VP
          (ADVP (RB:[1743..1751] strongly))
          (VBN:[1752..1761] inhibited)
          (NP-1 (-NONE-:[1761..1761] *))
          (PP=2
            (PP (IN:[1762..1764] by)
              (NP-LGS (DT:[1765..1767] an)
                
                (NML (AFX:[1769..1773] anti) (HYPH:[1773..1774] -)
                     (NN:[1774..1780] CYP3A4))
                (NN:[1781..1789] antibody)))
            (CC:[1790..1793] and)
            (PP (IN:[1794..1796] by)
              (NP-LGS (NN:[1797..1809] ketoconazole)))))
        (CC:[1810..1813] but)
        (VP (RB:[1814..1817] not)
          (PP=2 (IN:[1818..1820] by)
            (NP-LGS
              (NP (JJ:[1821..1826] other) (NNS:[1827..1837] inhibitors))
              (VP (VBN:[1838..1842] used)
                (NP (-NONE-:[1842..1842] *))))))))
    (.:[1842..1843] .)))

;sentence 12 Span:1844..1961
;These  results strongly suggest that NE-100 has different profiles regarding
;metabolism  between liver and intestine.
;[1881..1887]:substance:"NE-100"
(SENT
  (S
    (NP-SBJ (DT:[1844..1849] These) (NNS:[1851..1858] results))
    (ADVP (RB:[1859..1867] strongly))
    (VP (VBP:[1868..1875] suggest)
      (SBAR (IN:[1876..1880] that)
        (S
          (NP-SBJ (NN:[1881..1887] NE-100))
          (VP (VBZ:[1888..1891] has)
            (NP
              (NP (JJ:[1892..1901] different) (NNS:[1902..1910] profiles))
              (VP (VBG:[1911..1920] regarding)
                (NP (NN:[1921..1931] metabolism)))
              (PP (IN:[1933..1940] between)
                (NP (NN:[1941..1946] liver) (CC:[1947..1950] and)
                    (NN:[1951..1960] intestine))))))))
    (.:[1960..1961] .)))

;sentence 13 Span:1962..2114
;During absorption, NE-100 is mainly metabolized by  CYP3A4 in the intestine
;and thereafter by CYP2D6 in the liver in the presence of  therapeutic doses.
;[1981..1987]:substance:"NE-100"
;[2014..2020]:cyp450:"CYP3A4"
;[2056..2062]:cyp450:"CYP2D6"
(SENT
  (S
    (PP (IN:[1962..1968] During)
      (NP (NN:[1969..1979] absorption)))
    (,:[1979..1980] ,)
    (NP-SBJ-1 (NN:[1981..1987] NE-100))
    (VP (VBZ:[1988..1990] is)
      (VP
        (VP
          (ADVP (RB:[1991..1997] mainly))
          (VBN:[1998..2009] metabolized)
          (NP-1 (-NONE-:[2009..2009] *))
          (PP=2 (IN:[2010..2012] by)
            (NP-LGS (NN:[2014..2020] CYP3A4)))
          (PP-LOC=3 (IN:[2021..2023] in)
            (NP (DT:[2024..2027] the) (NN:[2028..2037] intestine))))
        (CC:[2038..2041] and)
        (VP
          (ADVP (RB:[2042..2052] thereafter))
          (PP=2 (IN:[2053..2055] by)
            (NP (NN:[2056..2062] CYP2D6)))
          (PP-LOC=3 (IN:[2063..2065] in)
            (NP (DT:[2066..2069] the) (NN:[2070..2075] liver)))
          (PP (IN:[2076..2078] in)
            (NP
              (NP (DT:[2079..2082] the) (NN:[2083..2091] presence))
              (PP (IN:[2092..2094] of)
                (NP (JJ:[2096..2107] therapeutic) (NNS:[2108..2113] doses))))))))
    (.:[2113..2114] .)))

;section 14 Span:2118..2163
;PMID: 12485954 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2118..2122] PMID) (::[2122..2123] :) (CD:[2124..2132] 12485954)
        (IN:[2133..2134] -LSB-) (NNP:[2134..2140] PubMed) (HYPH:[2141..2142] -)
        (JJ:[2143..2150] indexed) (IN:[2151..2154] for)
        (NNP:[2155..2163] MEDLINE-RSB-)))
